Newsroom

Sorted by: Latest

-

NATIXIS UK Regulatory Announcement: Form 8.3 Beazley plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

HemoSonics to be Honored at Premier, Inc.’s Annual Supplier Innovation Celebration

DURHAM, N.C.--(BUSINESS WIRE)--HemoSonics LLC announced today that it will be honored during Premier’s annual Supplier Innovation Celebration at its 2026 Breakthroughs Conference and Exhibition. The Innovation Celebration recognizes groundbreaking healthcare technologies launched throughout the year and highlights how these products help improve the health of communities. “Premier’s recognition of the Quantra Systems clearance in Obstetrics reinforces our commitment to delivering rapid, actiona...
-

Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen (patented nicotinamide riboside or NR) to date. “This agreement reflects the next stage of responsible NAD+ science,” said Rob Fried,...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a tru...
-

Hyatt Names Amar Lalvani Its First Chief Creative Officer

CHICAGO--(BUSINESS WIRE)--Hyatt Hotels Corporation (NYSE: H) today announced that Amar Lalvani has been appointed Hyatt’s first-ever Chief Creative Officer, in addition to his role as President & Creative Director of the company’s Lifestyle Group, effective immediately. Lalvani will continue to serve on Hyatt’s senior leadership team and report to Mark Hoplamazian, Hyatt’s Chairman, President and Chief Executive Officer. The appointment reflects Hyatt’s continued evolution as a more insight...
-

Hilton Capital Makes Strategic Minority Investment in New Century Advisors

GARDEN CITY, N.Y.--(BUSINESS WIRE)--Hilton Capital Management "Hilton Capital" has acquired a strategic minority, non-controlling stake in New Century Advisors ("NCA")....
-

VanEck Reduces Management Fee for Emerging Markets Bond ETF (EMBX)

NEW YORK--(BUSINESS WIRE)--VanEck today announced a reduction in the management fee for the VanEck Emerging Markets Bond ETF (EMBX), effective September 30, 2026. EMBX's total expense ratio will decrease from 0.76% to 0.65%. The reduction comes as EMBX continues to build on its long-term track record. Over the past five years, the Fund has delivered an annualized return of 4.7% per year, compared with 2.3% for its benchmark and -2.4% for 10-year U.S. Treasuries. Since its inception in 2012, the...
-

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinically meaningful functional benefit of ELEVIDYS (delandistrogene moxeparvovec) in older ambulatory patients with Duchenne muscular dystrophy. In ambulatory patients treated at ages 8 to 12, an age range in which functional decline becomes even m...
-

TP-Link Opens Pre-Orders for Archer 8 Ultra, Its First Wi-Fi 8 Router

IRVINE, Calif.--(BUSINESS WIRE)--TP-Link Systems Inc. today announced the availability of Archer 8 Ultra, its first Wi-Fi 8 router, marking the arrival of a new generation of home connectivity. Wi-Fi 8 represents a turning point for the networking industry. Where previous generations chased peak speeds, Wi-Fi 8 is engineered for consistency, holding performance steady in the harsh, real-world conditions users face every day. "Wi‑Fi 8 sets a new foundation, and we’ve built beyond it,” said Jim P...
-

UDC Korea Honored with Forbes 2026 Korea Trusted Innovation Award

EWING, N.J. & PANGYO, SOUTH KOREA--(BUSINESS WIRE)--UDC Korea received the Forbes 2026 Korea Trusted Innovation Award in Technology Innovation for phosphorescent OLED materials and technology....